Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Radiopharm Theranostics Ltd
RADX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.6800
-0.0876
-11.41%
Ult. Agg.: Nov 17, 11:55 AM
Get Report
Panoramica
Notizie
Grafici
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Rapporto azionario
Radiopharm Theranostics Financials
Radiopharm Theranostics (RADX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027
Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of
Benzinga Newsdesk
PRO
Radiopharm Theranostics Reported FY25 Cash Balance Of $29.12M, Operating Cash Flow Of $36.67M, Confirmed Guidance of Cash Runway Through To Mid-2026
Financial updateThe following is a summary of the Appendix 4C Cash Flow Report:The year-end closing cash balance was $29.12 million, a rise from $18.58 million at the close of the previous year.Net cash outflows from
Benzinga Newsdesk